Stoke Therapeutics (NASDAQ:STOK) Shares Down 3.8%

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) fell 3.8% during mid-day trading on Tuesday . The stock traded as low as $14.18 and last traded at $14.28. 51,646 shares were traded during mid-day trading, a decline of 94% from the average session volume of 835,896 shares. The stock had previously closed at $14.84.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on STOK shares. Canaccord Genuity Group decreased their target price on Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. Wedbush reaffirmed an “outperform” rating and set a $17.00 target price on shares of Stoke Therapeutics in a research report on Thursday, July 11th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $21.40.

Stoke Therapeutics Trading Down 0.7 %

The company has a market capitalization of $775.53 million, a PE ratio of -6.16 and a beta of 0.87. The stock has a fifty day moving average of $14.34 and a two-hundred day moving average of $11.72.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The company had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.33 million. Equities analysts forecast that Stoke Therapeutics, Inc. will post -2.23 EPS for the current year.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the transaction, the insider now directly owns 2,485 shares in the company, valued at approximately $34,168.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at about $29,000. Nisa Investment Advisors LLC raised its stake in Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after acquiring an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Stoke Therapeutics in the second quarter worth approximately $123,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Stoke Therapeutics in the first quarter worth $141,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after buying an additional 1,994 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.